RIPTACs for Precision Cancer Therapy: A Novel Modality with the Inspiration of HLD-0915 as the First Candidate in Clinical Trials

Authors

Zonghui Ma, Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch (UTMB), Galveston, Texas 77555, United States.
Cun Zhang, Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch (UTMB), Galveston, Texas 77555, United States.
Qiang Shen, LSU Health Sciences Center - New OrleansFollow
Jia Zhou, Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch (UTMB), Galveston, Texas 77555, United States.

Document Type

Editorial

Publication Date

6-12-2025

Publication Title

Journal of medicinal chemistry

First Page

10503

Last Page

10506

PubMed ID

40501287

Volume

68

Issue

11

Recommended Citation

Ma, Zonghui; Zhang, Cun; Shen, Qiang; and Zhou, Jia, "RIPTACs for Precision Cancer Therapy: A Novel Modality with the Inspiration of HLD-0915 as the First Candidate in Clinical Trials" (2025). School of Medicine Faculty Publications. 3913.
https://digitalscholar.lsuhsc.edu/som_facpubs/3913
10.1021/acs.jmedchem.5c01250